10-Q quarterly report · filed Nov 12, 2026

4D Molecular Therapeutics, Inc. (FDMT) Q3 2026 10-Q Quarterly Report

Short answer

4D Molecular Therapeutics, Inc. (FDMT) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $4M (up 4506.7% year over year) with net income of −$78M.

Q3 2026 key financials · XBRL

Revenue
$4M
+4506.7% YoY · +9.7% QoQ
Net income
−$78M
−37.2% YoY · −7.0% QoQ
Operating margin
-1958.9%
EPS (diluted)
−$1.08
−6.9% YoY · −3.8% QoQ

Source: XBRL data from the 4D Molecular Therapeutics, Inc. (FDMT) Q3 2026 10-Q on SEC EDGAR. USD.

4D Molecular Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $4.1M, up $4.1M YoY, driven by Otsuka clinical development cost sharing and reimbursements
  • Net loss $78.1M vs $56.9M YoY, operating loss $81.2M vs $61.2M
  • Worst-performing area: 4D-150 R&D expenses $43.1M, up $18.1M YoY
  • Cash, equivalents and marketable securities $375.0M, operating cash used $194.8M for nine months
  • Topline data expected in Q2 2027 for 4FRONT-1, with additional funding required and losses expected to continue

Risk Factors

  • Newly triggered debt risk: June 2026 Hercules Loan Agreement, $20.0 million funded against $200.0 million facility
  • Financial risk: $375.0 million in cash, cash equivalents and marketable securities funds planned operations for at least one year
  • Regulatory risk: April 2026 proclamation imposes Section 232 tariffs on imported brand pharmaceuticals, biologics and ingredients beginning July 31, 2026
  • Operational risk: September 2026 launch of 4SIGHT Phase 3 DME trial creates enrollment and execution exposure
  • Competitive risk: Approved therapies from Regeneron, Roche, Vertex and others may hinder physician and payer adoption

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other 4D Molecular Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.